Comparative in vitro activity of faropenem and 11 other antimicrobial agents against 405 aerobic and anaerobic pathogens isolated from skin and soft tissue infections from animal and human bites

被引：23

作者：

Goldstein, EJC

Citron, DM

Merriam, CV

Warren, YA

Tyrrell, KL

Fernandez, HT

机构：

[1] Santa Monica UCLA Med Ctr, RM Alden Res Lab, Santa Monica, CA 90404 USA

[2] Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90073 USA

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2002年 / 50卷 / 03期

关键词：

faropenem; bite wounds; Pasteurella; anaerobes; cellulitis;

D O I：

10.1093/jac/dkf139

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Faropenem, a new oral beta-lactam agent with a penem structure, was very active against 405 aerobic and anaerobic bite isolates. It inhibited 232 of 236 (98%) aerobic isolates, including all Pasteurella spp. and Eikenella corrodens at less than or equal to0.25 mg/L, and 164/169 (97%) anaerobic isolates, at less than or equal to1 mg/L. The 10 isolates that required greater than or equal to2 mg/L for inhibition were one strain each of Acinetobacter lwoffi, Corynebacterium minutissimum, Bacteroides ovatus, Lactobacillus delbrueckii and Peptostreptococcus tetradius, plus Corynebacterium 'aquaticum' (two strains) and Veillonella sp. (three strains).

引用

收藏

页码：411 / 420

页数：10

相关论文

共 10 条

[1] Pharmacodynamic properties of faropenem demonstrated by studies of time-kill kinetics and postantibiotic effect [J].

Boswell, FJ ;

Andrews, JM ;

Wise, R .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 (03) :415-418

[2] Activities of faropenem, an oral β-lactam, against recent US isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis [J].

Critchley, IA ;

Karlowsky, JA ;

Draghi, DC ;

Jones, ME ;

Thornsberry, C ;

Murfitt, K ;

Sahm, DF .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (02) :550-555

[3] Trovafloxacin compared with levofloxacin, ofloxacin, ciprofloxacin, azithromycin and clarithromycin against unusual aerobic and anaerobic human and animal bite-wound pathogens [J].

Goldstein, EJC ;

Citron, DM ;

Hudspeth, M ;

Gerardo, SH ;

Merriam, CV .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 41 (03) :391-396

[4] Comparative in vitro activity of ertapenem and 11 other antimicrobial agents against aerobic and anaerobic pathogens isolated from skin and soft tissue animal and human bite wound infections [J].

Goldstein, EJC ;

Citron, DM ;

Merriam, CV ;

Warren, YA ;

Tyrrell, K ;

Fernandez, H .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (05) :641-651

[5] In vitro antibacterial activity of LJC 11,036, an active metabolite of L-084, a new oral carbapenem antibiotic with potent antipneumococcal activity [J].

Hikida, M ;

Itahashi, K ;

Igarashi, A ;

Shiba, T ;

Kitamura, M .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (08) :2010-2016

[6] In vitro and in vivo antibacterial activities of L-084, a novel oral carbapenem, against causative organisms of respiratory tract infections [J].

Miyazaki, S ;

Hosoyama, T ;

Furuya, N ;

Ishii, Y ;

Matsumoto, T ;

Ohno, A ;

Tateda, K ;

Yamaguchi, K .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (01) :203-207

[7] Faropenem enhances superoxide anion production by human neutrophils in vitro [J].

Sato, K ;

Sato, N ;

Shimizu, H ;

Tsutiya, T ;

Takahashi, H ;

Kakizaki, S ;

Takayama, H ;

Takagi, H ;

Mori, M .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (03) :337-341

[8] Bacteriologic analysis of infected dog and cat bites [J].

Talan, DA ;

Citron, DM ;

Abrahamian, FM ;

Moran, GJ ;

Goldstein, EJC .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (02) :85-92

[9]

VONEIFF C, 2001, P 41 INT C ANT AG CH, P184

[10] The in-vitro activity of faropenem, a novel oral penem [J].

Woodcock, JM ;

Andrews, JM ;

Brenwald, NP ;

Ashby, JP ;

Wise, R .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 (01) :35-43